Abstract Number: 1013 • 2017 ACR/ARHP Annual Meeting
HLA-Class II Associations with ANCA-Associated Vasculitis in the Japanese Population: Different Features from European Populations
Background/Purpose: HLA-class II region harbors the strongest genetic factors for ANCA-associated vasculitis (AAV), and differences in the genetic background of HLA-class II may partly explain…Abstract Number: 1771 • 2017 ACR/ARHP Annual Meeting
Prevalence and Prognostic Relevance of Cardiovascular Involvement in ANCA-Associated Vasculitis: A Retrospective Cohort Study
Background/Purpose: Cardiovascular involvement in ANCA-associated vasculitis (AAV) including microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA), has long been regarded…Abstract Number: 1288 • 2017 ACR/ARHP Annual Meeting
Renal Disease Course in Pediatric Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis in the First 12-Months – a Pediatric Vasculitis Initiative (PedVas) Study
Background/Purpose: Renal disease is the most common manifestation of pediatric anti-neutrophil cycloplasmic antibody (ANCA) associated vasculitis (AAV). Renal disease course and early trajectories have not…Abstract Number: 1772 • 2017 ACR/ARHP Annual Meeting
Non-Protocolized Re-Biopsy in Patients with ANCA-Associated Glomerulonephritis: ¿Is It Necessary?
Background/Purpose: Protocolized and non-protocolized repeat renal biopsies are rarely performed in ANCA glomerulonephritis. Their role in predicting long term renal outcomes and aiding in clinical…Abstract Number: 1289 • 2017 ACR/ARHP Annual Meeting
Assessing ACR/EULAR Provisional 2017 Classification Criteria for Granulomatosis with Polyangiitis (GPA) in a Cohort of 376 Children with Small to Medium Vessel Chronic Vasculitis – a Pediatric Vasculitis Initiative (PedVas) Study
Background/Purpose: Classification of chronic vasculitis to clinically or etiologically meaningful groups has been challenging. In 2008, the 1990 ACR classification criteria for GPA was adapted…Abstract Number: 1773 • 2017 ACR/ARHP Annual Meeting
New Use for an Old Drug: Hydroxychloroquine for the Treatment of ANCA Associated Vasculitis
Background/Purpose: To assess retrospectively the efficacy and safety of hydroxychloroquine in patients with ANCA associated vasculitis. There is an unmet need for a corticosteroid sparing, non-toxic…Abstract Number: 16L • 2016 ACR/ARHP Annual Meeting
Comparison of Systematic Vs Individually Tailored Rituximab Regimen to Maintain ANCA-Associated–Vasculitis Remission: Results of a Prospective, Randomized–Controlled, Phase 3 Trial
Background/Purpose: Remission of ANCA-associated vasculitides (AAVs) can be induced with combined glucocorticoids and cyclophosphamide or rituximab (RTX) with comparable efficacy.1 RTX superiority to azathioprine was…Abstract Number: 1938 • 2016 ACR/ARHP Annual Meeting
Bronchiectasis Are Highly Prevalent in Anti-MPO ANCA-Associated Vasculitis and Associate with a Distinct Disease Phenotype
Background/Purpose: To assess the prevalence of bronchiectasis in a western cohort of ANCA positive GPA or MPA and its correlations with disease phenotype and outcome.…Abstract Number: 2396 • 2016 ACR/ARHP Annual Meeting
Initiation of Dialysis in Pediatric ANCA-Associated Vasculitis
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of rare systemic vasculitidies with significant morbidity and mortality. There have been no comparative effectiveness studies of AAV…Abstract Number: 1939 • 2016 ACR/ARHP Annual Meeting
Immunologic, Clinical and Demographic Correlates in 51 Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies
Background/Purpose: Exposure to illicit cocaine and its frequent adulterant, levamisole, is associated with the development of serum anti-neutrophil cytoplasmic autoantibodies (ANCA) and a variety of…Abstract Number: 2939 • 2016 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-Analysis
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-analysis Background/Purpose: Venous thromboembolism (VTE) is a common medical problem with a…Abstract Number: 126 • 2016 ACR/ARHP Annual Meeting
Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in African-American Patients: Disease Associations and Clinical Outcomes in an Urban Cohort
Background/Purpose: Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) has been most extensively described and studied in non-African-American populations. The significance of and associations with ANCA in African-Americans,…Abstract Number: 1940 • 2016 ACR/ARHP Annual Meeting
High Prevalence of Inflammatory Heart Disease in Eosinophillic Granulomatosis with Polyangiitis (Churg Strauss) Patients
Background/Purpose: To establish EGPA/Churg Strauss inflammatory heart disease prevalence and develop an algorithm for heart disease screening in EGPA patients. Methods: An audit of all…Abstract Number: 3045 • 2016 ACR/ARHP Annual Meeting
Immunometabolism in ANCA-Associated Glomerulonephritis
Background/Purpose: Mounting an inflammatory response requires immune cells to undergo major changes in metabolism. Mediators such as cytokines can specifically alter the metabolism of different…Abstract Number: 127 • 2016 ACR/ARHP Annual Meeting
Disease Characteristics and Outcomes in African-American Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: a High Risk Group for Poor Outcomes
Background/Purpose: Antineutrophil antibody-associated vasculitis (AAV) has been most extensively described and studied in non-African American populations. Little is known about the characteristics and outcomes of…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 21
- Next Page »